NEW ENGLAND GYNECOLOGY PLLC
Publications &
Presentations
A record of peer-reviewed scholarship, international presentations, and invited lectures spanning gynecologic oncology, translational science, cancer prevention, and reproductive medicine — spanning more than 15 years of active investigation.
13
PEER-REVIEWED PUBLICATIONS
20
PUBLISHED ARTIFACTS
31+
PRESENTATIONS & LECTURES
3
AD-HOC REVIEWER JOURNALS
REPORTS OF ORIGINAL WORK · CASE REPORTS · REVIEW ARTICLES
Peer-Reviewed
Publications
Citation source: Google Scholar. Impact factor source: respective journal websites.
LANDMARK CONTRIBUTIONS
- Three publications form the core scientific arc: OPAL Trial (2024) · OVARIO Phase II (2022) · Cisplatin Resistance & Oxidative Stress (2014)
ORIGINAL RESEARCH
2024 · LANDMARK
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J, Felicetti B, Baines AJ, YoussefAgha A, Rojas-Espaillat L, Ortiz AG, Provencher D, Vázquez RM, Cortijo LG, Zeng X.
Trials. 2024 May 4;25(1):301.
2022 · LANDMARK
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab (NCT03326193).
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL.
Gynecologic Oncology. 2022 Jun 8; S0090-8258(22)00331-6.
ORIGINAL RESEARCH · 2017
Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM, Belotte J, Saed MG, Memaj I, Diamond MP, Morris RT, Saed GM.
Free Radical Biology and Medicine. 2017 Jan;102:122–132.
- Role: Design, Data Analysis, Manuscript Writing
ORIGINAL RESEARCH · 2016
The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.
Nusrat O, Belotte J, Fletcher NM, Memaj I, Saed MG, Diamond MP, Saed GM.
Reproductive Sciences. 2016 Apr 26. pii: 1933719116645191.
- Role: Study Conception, Design, Data Analysis, Manuscript Writing
ORIGINAL RESEARCH · 2015
A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.
Belotte J, Fletcher NM, Saed MG, Abusamaan MS, Dyson G, Diamond MP, Saed GM.
PLOS ONE. 2015 Aug 24;10(8):e0135739.
ORIGINAL RESEARCH · 2015
Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Belotte J, Fletcher NM, Alexis M, Morris RT, Munkarah AR, Diamond MP, Saed GM.
Reproductive Sciences. 2015 Jan;22(1):38–46.
2014 · LANDMARK
The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer.
Belotte J, Fletcher NM, Awonuga AO, Alexis M, Abu-Soud HM, Saed MG, Diamond MP, Saed GM.
Reproductive Sciences. 2014 Apr;21(4):503–8.
ORIGINAL RESEARCH · 2012
Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer.
Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, Diamond MP, Abu-Soud HM, Saed GM.
Cancer Biomarkers. 2012;10(6):267–75.
- Role: Study Conception, Design, Data Analysis, Manuscript Writing
CASE REPORTS
CASE REPORT · 2014
Successful laparoscopic management of ruptured tubal pregnancy with an ipsilateral ectopic pelvic kidney.
Belotte J, Belotte J, Alexis M, Awonuga AO, Aguin TJ.
Case Reports in Obstetrics and Gynecology. 2014;2014:682737.
CASE REPORT · 2012
Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva.
Belotte J, Awonuga AO, Bolinjkar R, Alexis M, Tabassum F, Deppe G.
Obstetrics & Gynecology. 2012 Aug;120(2 Pt 2):458–60.
REVIEW ARTICLES
REVIEW · 2014
Advances in the Pathogenesis of Adhesion Development: The Role of Oxidative Stress.
Awonuga AO, Belotte J, Abuanzeh S, Fletcher NM, Diamond MP, Saed GM.
Reproductive Sciences. 2014 Feb;21(7):823–836.
CONFERENCE PROCEEDINGS & PUBLISHED ABSTRACTS
Published
Abstracts
20 published abstracts spanning GSK Phase 1/2 oncology trials, OVARIO, and foundational ovarian cancer science presented at SGO, AACR, SRI, ASRM, and AAGL.
JCO · 2025
A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.
Samnotra V, Belotte J, Shtessel L, Hanafin P, Pannirselvam M, Bhaskar A, Krishnatry AS, Rogan D, Yuzugullu H, Barve MA, Bedard P, Chu QS, Munster PN, Spira AI, Saleh RR, Sommerhalder D, Yap TA, Van Tine BA, Sanicola-Nadel M.
Journal of Clinical Oncology. Volume 43, Number 16_suppl. TPS3174. 2025.
SGO · 2025
A phase 2 study of niraparib plus bevacizumab maintenance following front-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis from the OVARIO study.
Hardesty MM, Krivak TC, Wright GS, et al. including Belotte J.
SGO Annual Meeting on Women’s Cancer. Abstract 836266. Seattle, WA. March 14–17, 2025.
GYNECOL ONCOL · 2023
Open-label, phase 2, randomized controlled multicenter study comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in participants with homologous recombination deficient stage III/IV ovarian cancer: Trial in progress.
Zeng X, Belotte J, Felicetti B, Baines A, YoussefAgha A, Rojas-Espaillat L, Ortiz AG, Provencher D, Vázquez RM, González-Cortijo L.
Gynecologic Oncology. Abstract 1252. 2023.
GYNECOL ONCOL · 2022
Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Frontline Platinum-Based Chemotherapy with Bevacizumab.
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL.
Gynecologic Oncology. Open Access. June 8, 2022.
GYNECOL ONCOL · 2021
Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab.
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton E, Chen J, Clements A, Gray H, Konecny G, Moore R, Richardson D.
Gynecologic Oncology. Volume 162, Supplement 1. 2021. Page S17.
REPROD SCI · 2016
Glutathione Peroxidase Significantly Increased Proliferation of Both A2780 and A2780Cis Ovarian Cancer Cell Lines.
Belotte J, Fletcher NM, Saed MG, Diamond MP, Saed GM.
Reproductive Sciences. Vol. 23, Supplement 1, Late-Breaking Abstract. March 2016.
REPROD SCI · 2016
Nusrat O, Belotte J, Fletcher NM, Dai J, Memaj I, Saed GM.
Reproductive Sciences. Vol. 23, Supplement 1, Page 178A, Abstract T-250. March 2016.
REPROD SCI · 2016
Fletcher NM, Belotte J, Saed MG, Abusamaan MS, Diamond MP, Saed GM.
Reproductive Sciences. Vol. 23, Supplement 1, Page 262A, Abstract F-248. March 2016.
REPROD SCI · 2016
Detti L, Fletcher NM, Uhlmann RA, Belotte J, Williams LJ, Saed GM.
Reproductive Sciences. Vol. 23, Supplement 1, Page 180A, Abstract T-257. March 2016.
CLIN CANCER RES · 2015
Belotte J, Nusrat O, Fletcher NM, Saed MG, Neubauer BR, Abu-Soud HM.
Clinical Cancer Research. Volume 21, Issue 4 Supplement. Abstract B01. Published February 13, 2015.
FERTIL STERIL · 2014
Awonuga AO, Fletcher NM, Nusrat O, Saed MG, Abusamaan MS, Belotte J, Diamond MP, Saed GM.
Fertility and Sterility. Volume 102, Issue 3 Supplement, Page e73. Abstract O-213. August 2014.
REPROD SCI · 2014
Saed MG, Saed GM, Fletcher NM, Belotte J, Levin NK, Tainsky MA, Diamond MP.
Reproductive Sciences. Vol. 21, No. 3 (Supplement 1), Page 213A, Abstract T-249. March 2014.
REPROD SCI · 2014
Fletcher NM, Belotte J, Saed GM, Abu-Soud HM, Diamond MP, Saed GM.
Reproductive Sciences. Vol. 21, No. 3 (Supplement 1), Page 207A, Abstract T-228. March 2014.
REPROD SCI · 2014
Belotte J, Fletcher NM, Diamond MP, Saed GM.
Reproductive Sciences. Vol. 21, No. 3 (Supplement 1), Page 204A, Abstract T-219. March 2014.
CLIN CANCER RES · 2014
Belotte J, Fletcher NM, Levin NK, Simon MS, Abu-Soud HM, Diamond MP, Tainsky MA, Saed GM.
CLIN CANCER RES · 2013
Belotte J, Fletcher NM, Levin NK, Simon MS, Abu-Soud HM, Diamond MP, Tainsky MA, Saed GM.
REPROD SCI · 2012
Fletcher NM, Belotte J, Diamond MP, Saed GM.
JMIG · 2012
Bolinjkar RS, Belotte J, Hussein Y, Dean M, Hendrix S.
JMIG · 2011
Bolinjkar RS, Belotte J.
JMIG · 2010
Belotte J, Filetti CL, Shavell VI, Berman JM, Yancy AF.
NON-PEER-REVIEWED PUBLICATIONS
Public &
Professional Writing
OP-ED · 2016
Increasing HPV Immunization Rate as an Elegant Strategy to Reduce Cancer Health Disparities in Michigan: Killing Two Birds With One Stone!
Belotte J.
PODIUM & POSTER PRESENTATIONS
Scientific
Presentations
Refereed and non-refereed podium and poster presentations at international, national, and regional scientific meetings.
PODIUM PRESENTATIONS — REFEREED
PODIUM · REFEREED
“The Role of Oxidative Stress in the Establishment of Cisplatin Resistance in Epithelial Ovarian Cancer Cells: Additional Evidence”
NIH Women’s Reproductive Health Research (WRHR) Retreat
Augusta, GA · December 1–2, 2016
PODIUM · REFEREED
“Small Bowel Obstruction Due to Essure Micro-Insert Migration”
AAGL Global Congress of Minimally Invasive Gynecology — 39th Annual Meeting
Las Vegas, NV · November 2010
POSTER PRESENTATIONS — REFEREED
PODIUM · NON-REFEREED
“The in-vivo effects of superoxide dismutase on the incidence and severity of post-operative adhesion development after cecal abrasion”
3rd Annual C.S. Mott Center Scientific Retreat — Wayne State University
PODIUM · NON-REFEREED
“A novel association between a catalase single nucleotide polymorphism and increased risk of ovarian cancer”
3rd Annual C.S. Mott Center Scientific Retreat — Wayne State University
Detroit, MI · May 15, 2013
POSTER PRESENTATIONS — REFEREED
POSTER · REFEREED
“Clinical Survival Outcomes Trend of Squamous Vaginal Cancer In The United States: A SEER Based Study”
NIH WRHR Retreat
Augusta, GA · December 1–2, 2016
POSTER · REFEREED
“Glutathione Peroxidase Significantly Increased Proliferation of Both A2780 and A2780Cis Ovarian Cancer Cell Lines”
Society for Reproductive Investigation — 63rd Annual Scientific Meeting
Montreal, Canada · March 16–19, 2016
POSTER · REFEREED
“Chemoresistant Ovarian Cancer Cells Manifest Lower VEGF and HIF-1α: A Potential Survival Mechanism”
Society for Reproductive Investigation — 63rd Annual Scientific Meeting
Montreal, Canada · March 16–19, 2016
POSTER · REFEREED
“Chemotherapy Induces a Genotype Switch in Key Antioxidant Enzymes: A Potential Mechanism of Chemoresistance”
Society for Reproductive Investigation — 63rd Annual Scientific Meeting
Montreal, Canada · March 16–19, 2016
POSTER · REFEREED
“The in-vivo effects of superoxide dismutase on post-operative adhesion development”
ASRM 70th Annual Meeting
Honolulu, HI · October 18–22, 2014
POSTER · REFEREED
“Superoxide dismutase significantly reversed the development of cisplatin resistance in epithelial ovarian cancer”
AACR Precision Medicine Series: Drug Sensitivity and Resistance
POSTER · REFEREED
“SNPs in Key Oxidants and Antioxidants are Associated with Increased Risk and Serve as Potential Targets for Ovarian Cancer”
SGI 61st Annual Scientific Meeting — Florence, Italy
Florence, Italy · March 26–29, 2014
POSTER · REFEREED
“Dichloroacetate Increases Sensitivity to Chemotherapy by Modulation of Antioxidants in Epithelial Ovarian Cancer”
SGI 61st Annual Scientific Meeting — Florence, Italy
Florence, Italy · March 26–29, 2014
POSTER · REFEREED
“Sox2 Gene Amplification Impacts Survival in Epithelial Ovarian Cancer”
SGI 61st Annual Scientific Meeting — Florence, Italy
Florence, Italy · March 26–29, 2014
POSTER · REFEREED
“The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer”
Miami, FL · September 18–21, 2013
POSTER · REFEREED
“Catalase and NADPH oxidase SNPs are associated with increased risk and serve as potential targets for breast and ovarian cancers”
Washington, DC · April 10, 2013
POSTER · REFEREED
“Dichloroacetate increases sensitivity to chemotherapy treatment of epithelial ovarian cancer cells”
San Diego, CA · March 21–24, 2012
POSTER · REFEREED
“Persistent Trophoblastic Implant on the Right Ovary after Laparoscopic Salpingectomy for Ectopic Pregnancy”
Las Vegas, NV · November 2012
POSTER · REFEREED
“Case Report for Uretero-Vaginal Fistula: A Delayed Complication of Robotic Surgery”
Hollywood, FL · November 2011
POSTER · REFEREED
“Platinum based combination chemotherapy for the treatment of advanced stage squamous cell carcinoma of the vulva”
Lansing, MI · May 2011
POSTER · REFEREED
“Small Bowel Obstruction Subsequent to Essure Micro-Insert Sterilization: A Case Report”
Lansing, MI · May 2011
INTERNATIONAL, NATIONAL & REGIONAL
Invited
Lectures & Presentations
INTERNATIONAL / NATIONAL
2018
“Cancer Preventative Care: A Focus on HPV Vaccination and Gynecologic Cancers”
- INTERNATIONAL KEYNOTE
2010
“Management of Bowel Obstruction in the Setting of Ovarian Cancer”
- NATIONAL INVITED
2009
“Hormonal Disorders”
2009
“Diagnostic and Operative Laparoscopy”
LOCAL / REGIONAL
2018
Cervical Cancer Screening — Resident Lecture Series
- GRAND ROUNDS
2017
Updates on Ectopic Pregnancy — Fellow Lecture Series
2017
“The Role of Oxidative Stress in the Establishment of Cisplatin Resistance in Epithelial Ovarian Cancer Cells: Additional Evidence”
- INVITED RESEARCH LECTURE
2017
“Cancer Preventative Care: A Focus on HPV Vaccination”
2017
“Vaccines for Women’s Health: An Update for the Obstetrician/Gynecologist”
- GRAND ROUNDS
2017
Cancer Preventative Care: A Rare Opportunity to Reduce Both the Cancer Burden and Cancer Health Disparities — A Focus on HPV Vaccination and Gynecologic Cancers”
- GRAND ROUNDS
2017
“Advances and New Opportunities for Cancer Preventative Care for the OBGYN Generalist. HPV Vaccination as Means to Reduce the Cancer Burden and Cancer Health Disparities in the Urban Setting”
- GRAND ROUNDS
2016
“A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival”
2015
“Haïti: Past, Present and Future” — Keynote Speaker
- COMMUNITY KEYNOTE
2014
“New Insights into Cancer Issues in Women”
2013
“Epithelial Ovarian Cancer, Chemotherapy and Cisplatin Resistance”
2013
“Epithelial Ovarian Cancer, Chemotherapy and Cisplatin Resistance” — Brown Bag Seminar Series
2012
“Diagnostic and Operative Laparoscopy”
Ready to Build a
Smarter Learning Program?
Whether you are a residency program director, a health system executive, a research institution, or an organization committed to women’s health — NEG+ will design an education program that moves your team forward.